rather, cluster with specific types of AIDS-NHL: EBV infection is preferentially associated with LC-IBPL (4/4; 100%). while it is present in only a fraction of SNCCL (5/ 16; 31.2%) and LNCCL (1 /4; 25%); c-myc oncogene activation clusters with SNCCL (1 6/16; 1 OO%), whereas it is less frequent in LC-IBPL (1 /4; 25%) and LNCCL (2/4; 50%); p53 inactivation is restricted to SNCCL (1 0/16; 62.5%) and consistently associated with c-myc activation. These data show that AIDS-NHL are associated with multiple genetic lesions that involve both proto-oncogenes and tumor suppressor genes and may accumulate in the relatively short period of time (4 to 6 years) between human immunodeficiency virus infection and AIDS-NHL development. These genetic lesions differ in the various AIDS-NHL subtypes, suggesting the involvement of distinct molecular pathway. Formulation'' as high-grade NHL and display a histology consistent with small noncleaved cell lymphoma (SNCCL) or large cell immunoblastic-plasmacytoid lymphoma (LC-IBPL)," while 30% of cases are of intermediate-grade, histologically defined as diffuse large noncleaved cell lymphoma (LNCCL).I3 When compared with histologically similar lymphoid neoplasms arising in immunocompetent patients, systemic AIDS-NHL display distinctive features, including poor prognosis and the frequent involvement of extranodal sites, particularly the GI tract, liver, CNS, and bone marrow Many reports have focused on the clinico-pathological features of AIDS-NHL: however, far less is known about the genetic alterations underlying the pathogenesis of these tumors. Previous observations have indicated an association with chromosomal translocations involving the c-myc on~o g e n e . " -~~ In addition, Epstein-Barr virus (EBV) infection of the tumor cells has also been detected in 40% to 50% of systemic AIDS-NHL,22.24-28 and it has been suggested to play a pathogenetic role based on the observation that viral infection precedes clonal expansion in these tumors.29 Although EBV infection associated with c-myc oncogene activation is sufficient for the malignant transformation of human B cells in vitro,30 the identification of AIDS-NHL lacking one or both of these lesions22 suggests that alternative genetic lesions may be involved in the development of AIDS-NHL in vivo. In this respect, the role of several dominantly acting oncogenes relevant to B-cell lymphomagenesis, such as bcl-2 and bcl-1, as well as the presence of viral genomes other than EBV, has been ruled out by previous studies.20 -22 On the other hand, the role of tumor suppressor gene inactivation has not yet been investigated, although recent evidence suggests a role for these lesions in the pathogenesis of certain lymphoid malignancies. 10, [31] [32] [33] Based on these observations, this study has been aimed at a comprehensive analysis of a relatively large panel of cases to identify lesions associated with the pathogenesis of the various subtypes of AIDS-NHL. We found that AIDS-NHL can be characterized by the accumulation of multiple distinct (BM). 1.8-17.19 166 Blood, V o l 8 For personal use only. on November 11, 2017. by guest www.bloodjournal.org From
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genetic lesions within the same tumor. These lesions differ in the various AIDS-NHL histologic subtypes, suggesting that alternative molecular pathways may be associated with AIDSlymphomagenesis.
MATERIALS AND METHODS
Pathologic samples. Bioptic samples of lymph node, BM, peripheral blood, or other involved organs from 27 patients with AIDS were collected during standard diagnostic procedures. Approval was obtained from the institutional Review Board for these studies. Informed consent was provided according to the Declaration of Helsinki. In all instances, the specimen was collected at diagnosis before specific therapy. Most samples were derived from patients referred to institutions within the United States (Department of Pathology, New York University, New York, NY, and Division of Surgical Pathology, Department of Pathology, Columbia University, New York, NY); three cases were derived from the Universi~ di Torino, Italy. The histology of all cases has been reviewed by D.M.K. to ensure uniformity of diagnostic criteria. Diagnoses were based on analysis of hystopathology, immunophenotypic analysis of cell surface markers, and immunogenotypic analysis of Ig gene rearrangement." For most cases, the fraction of malignant cells in the pathologic specimen was greater than 80%, as determined by cell suspension cytofluorimetric or tissue section immunohistochemical analysis of cell surface markers and by Ig gene rearrangement analy~is.'~ For most samples, a mononuclear cell suspension of greater than 95% viability was prepared by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density gradient centrifugation.
DNA was purified by digestion with proteinase K, extraction with phenol/chloroform, and precipitation by ethanol." For Southern Blot analysi~,'~ IO to 15 pg of DNA was digested with the appropriate restriction endonuclease, electrophoresed in a 0.8% to 1% agarose gel, denatured, neutralized, transferred to Duralose filters (Strategene, La Jolla, CA), and hybridized to probes that had been "P-labeled by the random primer extension method.36 Filters were washed in 0.2 X SSC (NaCl/ Na citrate)/0.5% sodium dodecyl sulfate (SDS) (NaDodS04) for 2 hours at 60°C and then autoradiographed using intensifying screens (Quanta 111; Dupont, Boston, MA).
The organization of the c-myc locus was analyzed by hybridization of EcoRI and Hind111 digested DNA to the human c-myc probe MC413RC, representative of the third exon of the cmyc gene."^'* The presence of the EBV genome was investigated with a probe specific for the EBV genomic termini (5.2-kb BamHIEcoRI fragment isolated from the fused BamHI terminal fragment NJ-het).'9 To study the RBI locus, two subclones were derived from the full-length RBI cDNA (kind gift of Dr S. Friend, Harvard Medical School, Charlestown, MA)40 and used in Southern Blot analysis: probe 5'-RB 1 (.7-kb HpaI/EcoRI fragment) spanning exons 1 through 9, and probe 3'-RB 1 (EcoRI/EcoRI 3.9-kb fragment) spanning exons IO through 27.
All the oligonucleotides used for polymerase chain reaction (PCR) amplification in this study were synthesized using an Applied Biosystems (Foster City, CA) synthetizer. Names and sequences of p53 primers used in the present study have been previously reported." To analyze the first exon-first intron boundary region of the c-myc gene the following pairs of primers derived from the c-myc locus sequence4' were used FS, 5'-GCACTGGAACTTACAACACC-3' (nucleotides 27 16 through 2735) and F3', 5'-GGTGCTTACCTGGTTTTCCA-3' (nucleotides 287 1 through 289 I); GS, 5'-CTGCCAGGACCCGCTTCTCT-3' (nucleotides 2803 through 2822) and G3', S-TTTACCCCGATCCAG-TTCTG-3' (nucleotides 304 I through 3060). The oligonucleotides DNA extraction and Southern blot analysis.
DNA probes.
Oligonucleotide primers.
used to amplify sequences of K-Ras and H-Ras exons 1 and 2, as well as N-Ras exon 2, have been previously described4'; the following primers4' have been used to amplify sequences of N-Ras exon 1: N 1 a, 5'-GACTGAGTACAAACTGGTGG-3' and N 1 b, 5'-GGG-CCTCACCTCTATGGTG-3'. The following pairs of primers were derived from the sequence of the RB 1 geneu and were used to study RBI exons 10 through 27: exon IO, RBIO-5, S-TGTGTGCT-GAGAGATGTAAT-3', and RB 10-3, S-TACCTATATCAGTAT-CAACC-3'; exon 1 I, RBI 1-5, 5'-GATGCATAAAGCACAAATTG-3', and RB 1 1-3, 5'-GAAACACTATAAAGCCATGA-3'; exon 12, RB 12-5, S-CCTTCATTGCTTAACACATT-3', and RB 12-3, 5'-AGAACTCAGTACTTTAACTT-3'; exon 13, RBI 3-5, S-TCT-GATTACACAGTATCCTCY, and RB 1 3-3, 5'-ATACGAACT-GGAAAGATGCT-3'; exon 14, RB 14-5, 5'-CAGTGAGACTCC-ATCTCAAA-3', and RB 14-3, 5'-TCCCAAAGTGCTGGGATTG-3', exons 15 and 16, RBI 56a, S-ATGCTGACACAAATAAGT-3', and RBI 56b, Single strand conformation polymorphism (SSCFj analysis. SSCP analysis was modified from Orita et al ! 5 Briefly, PCRs were performed with 100 ng of genomic DNA, IO pmol of each primer, 2.5 pmol/L dNTPs, 1 FCi of [a-"P]dCTP (NEN, Boston, MA; specific activity, 3,000 Ci/mmol; 1 Ci = 37 GBq), IO mmol/L Tris-HCI (pH 8.8), 50 mmol/L KCI, 1 mmol/L MgCI2, 0.01% gelatin, 0.5 U Taq polymerase (Cetus, Emeryville, CA), in a final volume of IO pL. Thirty cycles of denaturation (94"C), annealing (annealing temperatures were optimized for each pair of primers), and extension (72°C) were performed in a temperature controller (DNA Thermal-Cycler; Perkin-Elmer Cetus). The reaction (2 pL) was diluted 1:25 in 0.1% NaDodS04 (SDS), 10 mmol/L EDTA, and further mixed 1:1 with sequencing stop solution.35 Samples were heated at 95°C for 5 minutes, chilled on ice, and immediately loaded (3 pL) onto a 6% acrylamide-TBE gel containing 10% glycerol. Gels were run at 8 W for 12 to 15 hours at room temperature, fixed in 10% acetic acid, air dried, and analyzed by autoradiography using an intensifying screen for 6 to 72 hours.
PCR was performed with 500 ng of genomic DNA, 20 pmol of each primer, 200 pmol/L dNTPs, IO mmol/L Tris-HCI (pH 8.8), 50 mmol/L KCI, 1 mmol/L MgCI2, 0.01% gelatin, 2.5 U Taq polymerase. The number and conditions of amplification cycles were as described above. Sequencing reactions were performed as previously reported." Briefly, IO pmol of one of the two primers used for DNA amplification were labeled with [y-32P] adenosine triphosphate (ATP) (NEN; specific activity, 3,000 Ci mmol) by means of T4 polynucleotide kinase (Biolabs, Beverly, MA) and purified through a Bio-gel P4 fine column (Bio-Rad, Richmond, CA). Approximately 0.25 pmol of each fragment, previously isolated CAGTGTAAACA-3'; RB27-5, T-GCCACTTGCCAACTTACCDirect sequencing of PCR products.
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RESULTS
Twenty-seven cases of systemic AIDS-NHL (1 6 SNCCL, 6 LNCCL, 5 LC-IBPL) were included in the present study; the main clinical features of each patient are reported in Table  1 . In all cases tested, a monoclonal pattern of Ig gene rearrangement was observed by Southern Blot analysis using a JH probe on EcoRI, HindIII, or BumHI DNA digests (see Table 1 ; not shown). The molecular analyses performed included the study of EBV infection, the activation of c-myc Therefore, when using a probe that recognizes the configuration of the viral genomic termini, multiple infection events are identified as multiple fragments of different size in Southern blot analysis, whereas a monomorphic pattern of episomal EBV genome documents a single infection event preceding
clonal expansion of the infected As shown in Tables I and 2 , EBV infection was detected in virtually all the LC-IBPL tested (4/4), while only in a minority of SNCCL ( 5 / 16) and LNCCL ( l /4). A single intense band was present in all the positive cases, indicating monoclonal infection (Fig I) . The size ofthe hybridizing fragments was consistent with the expected size of fused EBV termini, indicating that EBV is present in the episomal form in infected tumor cells. No small fragments, whose presence would suggest a linearized or integrated form of EBV genome, were detected in any of the AIDS-NHL studied (Fig I) .
The intensity of the hybridization signal is related to the copy number of EBV episomes in the tumor biopsies. After densitometric analysis normalized against a control cell line containing approximately 100 to 200 c~pies/cell?~ the estimated number ofepisomes in the AIDS-NHL samples varies from few to 100 copies/cell (data not shown). Immunofluorescence experiments performed using human a-EBNA-I antisera showed that EBV was present and expressed within the neoplastic population (data not shown).
Overall, these results define that EBV infection in AIDS-NHL ( I ) is a frequent event in LC-IBPL, while restricted to only a minority of SNCCL and LNCCL, and (2) Southem analysis were studied further to search for small deletions/insertions or point mutations in the region surrounding the first exon-first intron by the PCR-SSCP a p proach. Two DNA fragments, spanning 165 nucleotides 5' and I79 nucleotides 3'of the first intron-first exon boundary, which are known to harbor mutations in all cases of endemic BL and in those cases with variant translocations (J. Murphy, R. D.-F., unpublished observation, July 1992), were enzymatically amplified. Preliminary experiments using IO samples harboring independent mutations had demonstrated a 100% concordance between the PCR-SSCP and PCRdirect sequencing approaches (unpublished observation). Mutations were not detected in any of the AIDS-NHLs studied, indicating a normal configuration of the c-myc locus in these cases (not shown), Altogether, structural lesions indicative of c-myc oncogene activation were detected in 79. I% (l9/24) of AIDS-NHL cases tested. According to histology, c-myc lesions were uniformly present in SNCCL cases ( I6/ 16), but limited to a fraction of non-SNCCL AIDS-NHL (3/8; see Ta For personal use only. on November 11, 2017. by guest www.bloodjournal.org From for representative examples). including three SNCCL and one LC-IBPL (Tables 1 and 2 ).
The characteristics of Ras mutations in AIDS-NHL are described in Table 3 ; in three cases the N-Ras gene was involved (two A + T transversions at codon 6 1 and one G + A transition at codon 12). while in the remaining case, a G -c A transition was detected at K-Ras codon 12. The preferential involvement of the N-Ras gene, in contrast to the K-or H-Ras genes, is in agreement with the mutational spectrum usually found in hematologic malignancies."
In conclusion, Ras mutations, though infrequent and limited to a subset of AIDS-NHL, appear to be a distinctive feature of AIDSNHL in contrast to NHL of similar histology arising in nonimmunocompromised hosts.
The human RBI genomic locus spans approximately 200 kb and is composed of 27 exons4 Among theseveral mechanisms of RBI inactivation described in human tumors, point mutations. introducing stop codons or splicing errors. are most frequently encountered (80% of the lesions), while gross rearrangements or large intra-genic deletions represent a more rare event. 54 Southern blot analysis allows the identification of gross rearrangements or partial deletions within the locus, as demonstrated by various studie~"'~; therefore, as a first step, Hind111 digests from 24 AIDS-NHL were probed with 0.9-and 3.8-kb RBI cDNA clones, spanning the 5' (exons I through 9) and 3' (exons 9 through 27) regions. respectively. A normal genomic pattern was observed in all cases tested (data not shown).
We then undertook a thorough mutational analysis of the RBI locus by the PCR-SSCP technique (Fig 4) . We focused on exons IO through 27, which include two RBI domains (between amino acids 393 to 572 and 646 to 772, respectively), which are essential for RBI function and overlap the location of most naturally occurring mutations of the RBI gene in human t u m~r s .~~.~~ Individual exons and corresponding intronic sequences at both ends, in all cases including splicing sites. were PCR-amplified from genomic DNA of the AIDS-NHL cases. Tumor samples harboring known mutations (kind gift of Dr D. Yandell, Harvard Medical School, Boston, MA) were used as positive controls for most exons. Most AIDS-NHL samples tested showed a normal electrophoretic pattern, indicating the absence of mutations within the RBI domains studied (Fig 4) ; three cases displayed an altered SSCP migration in exon 26, which, on direct sequence analysis, was found to be caused by a previously reported population polym~rphism.~' RBI gencana/jais. Overall, our comprehensive analyses by a variety of technical approaches suggests that AIDS-lymphomagenesis is independent of RBI inactivation.
p53 inactivation in human tumors is most frequently caused by point mutations in the coding sequence of exons 5 through 9 in one allele with or without loss of the other allele.sx~s" To define the occurrence of p53 lesions in AIDS-NHL. a two-step strategy was devised, as previously reported.'' p53 exons 5 through 9 were analyzed in genomic DNA of 27 AIDS-NHL cases by the PCR-SSCP technique (Fig 5A) . Fragments displaying an altered electrophoretic mobility by SSCP analysis were then reamplified in a separate reaction and analyzed by PCRdirect sequencing p53 gene inacrivation.
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to confirm and characterize the nature of the mutation (representative examples are shown in Fig 59) . The overall rate of p53 mutations in AIDS-NHL was 37% (10/27; Table 2 ). However, p53 mutations were not randomly distributed among the different histologic types of AIDS NHL; rather, they were found only in SNCCL (10/16; 62.5%) and were consistently absent in all the LNCCL and LC-IBPL tested (Tables 1 and 2) . Analysis of the results by the Fisher's exact test showed that the p53 mutation rate is significantly different in SNCCL compared with both LC-IBPL (P = .046) and LNCCL (P = .024).
The characteristics of p53 mutations in AIDSNHL are described in Table 4 . Overall, p53 inactivation in AIDSNHL occurs by molecular mechanisms similar to that reported in other types of tumor^.^^*^^ In particular, the mutational spectrum identified in AIDSNHL does not significantly differ from what reported in NHL arising in the immunocompetent host.3' In most instances, the mutation was represented by a single base-pair substitution (10/13 p53 lesions observed), while three samples displayed gross rearrangements within the amplified product (two deletions and one insertion). The single base-pair substitutions found in AIDSNHL led to missense (nine events) or nonsense (one event) mutations. Transitions at CpG dinucleotides, the most frequent type of mutation in many human ~a n c e r s ,~~*~~ occurred in 6 of IO point mutational events. In three AIDSNHL samples, two p53 lesions were observed in the same tumor, either affecting two different exons of the gene (DK808 and RDF1296; Table   4 ) or involving two codons of the same exon (DK17 15; Table  4 ). In three other patients, the presence of a p53 mutation was accompanied by the loss of the other allele, as documented by the absence of the wild-type sequence. Our pre- For personal use only. on November 11, 2017. by guest www.bloodjournal.org From vious control studies3' had shown that the SSCP method, under our experimental conditions, is sensitive at the level of at least 1% and is specific, as evaluated by the 100% concordance between the results obtained by direct sequencing versus SSCP analysis of p53 exons 5 through 9; however, it cannot be formally excluded that exons other than the ones tested might be also affected in AIDS-NHL.
In summary, p53 inactivation among AIDS-NHL appears to be specifically associated with the SNCCL type (62.5%).
DISCUSSION
We have investigated the pathogenesis of AIDS-NHL by studying the frequency of EBV viral infection and the involvement of several oncogenes and tumor suppressor genes in these tumors. Overall, our results suggest that AIDS-NHL are associated with multiple genetic lesions underlying distinct molecular pathways in different histologic types, and that some of these pathways represent a peculiar feature of AIDS-NHL as opposed to NHL of similar histology developing in the immunocompetent host.
The association between EBV infection and lymphoid tumors is well established in immunodeficiency settings, in&ding AIDS.9.1 L'2. 22324-29 A pathogenetic role of EBV in AIDS lymphomagenesis is supported by the well-recognized finding that EBV transforms human B cells in vitro60 as well as by several lines of indirect evidence. First, it has been shown that one of the immunologic defects present in AIDS selectively impairs the immunosurveillance of EBV infected cells,6' resulting in their oligoclonal expansion." Second, there is a positive correlation between the appearance of EBV in Bcell clones at the stage of persistent generalized lymphadenopathy (PGL) and the eventual development of EBV-positive NHL.6' Third, EBV-termini analysisz9 (and this report) shows that EBV infection precedes clonal expansion of the malignant cell in all cases. Taken together, these observations suggest that EBV infection, in the context of immunodeficiency, leads to an expansion of a B-cell population at risk for additional genetic accidents leading to NHL. However, it remains to be investigated whether the expression of the putative EBV transforming proteins EBNA-2 and LMP are maintained in AIDS-NHL cells, or is repressed, as it is the case for endemic and sporadic BL. 63 The presence of EBV infection is not uniformly distributed throughout the different histotypes of AIDS-NHL. Among SNCCL the presence of EBV genome is limited to a fraction of samples, similar to that reported for sporadic BL developing in the immunocompetent host.'0922,29 On the contrary, we show that EBV infection represents a distinctive feature of systemic AIDS-LC-IBPL, being present in virtually all the samples tested. Because other NHL characterized by an immunoblastic phenotype, namely AIDS-NHL arising in the CNS@ and NHL arising in allograft re~ipients,g"~ also display a high rate (virtually 100%) of EBV infection, it is possible that a common genetic mechanism distinctly involving EBV may be associated with the pathogenesis of these malignancies.
This study extends previous o b s e~a t i o n s *~-~~~~~ that c-myc plays an important role in AIDS lymphomagenesis. c-myc is activated in a significant fraction (79.1%) of AIDS-NHL, including 100% of SNCCL and a subset of LNCCL and LC-IBPL. The molecular mechanisms leading to c-myc activation in AIDS-NHL are similar to sporadic BL, as opposed to endemic BL, in many respects. First, c-myc breakpoints consistently occur within the first exon, first intron, or flanking sequences of the gene in both AIDS-NHL and sporadic Burkitt lymphoma" (and this report). Second, the truncated c-myc recombines with the switch region of the IgH locus and the timing of the recombination event is believed to parallel the timing of IgH isotype switching, ie, occumng at a relatively late stage of B-cell d e v e l~p m e n t .~~~~~ Finally, the association with EBV infection in AIDS-SNCCL (-40%; this report and refs 10 and 22) is very similar to sporadic BL, rather than to endemic BL ( 100%10947). Altogether, the example of AIDS-NHL, as well as endemic BL and tumors developing in immunodeficient a n i m a l~, 6~,~~ suggests that c-myc activation is a genetic event frequently associated with lymphomagenesis in certain conditions of immunodeficiency, particularly those associated with chronic B-cell stimulation. A possible explanation for this phenomenon is that c-myc oncogene activation, besides deregulating B-cell growth and differentiation, may also cause other cellular alterations that are positively selected in immunodeficient states. One such alteration may be the downregulation of the integrin receptor LFA-1, which has been shown to be controlled by c-myc in B cells and which is involved in a variety of biologic functions including cell conjugate formation between B cells and cytotoxic T cells and natural killer cells.68 p53 inactivation represents a novel finding associated with AIDS-NHL; its pathogenetic relevance is underscored by the specific clustering of p53 lesions with the SNCCL histotype. In AIDS-SNCCL, p53 inactivation is detected at high frequency (62.5%), almost twice that observed in tumors of the same histology observed in the immunocompetent host.3'
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The frequent simultaneous occurrence of p53 inactivation and c-myc deregulation in the same tumor in vivo, observed in AIDS-NHL as well as in BL and L3-type B-cell acute lymphoblastic leukemia arising in the general p~p u l a t i o n ,~' suggests that cells carrying an activated c-myc oncogene may be under pressure to subsequently delete a p53-dependent pathway. This hypothesis is supported by several preliminary observation^^^ suggesting that the c-myc protein may be involved in regulation of p53 gene expression.
Finally, mutations of the Ras family proto-oncogenes are present in AIDS-NHL, although in a limited fraction of cases (14.8%). Ras activation appears to be a peculiar feature of AIDS-NHL in contrast to NHL of the same histologic type arising in the immunocompetent host. Indeed, in more than 40 NHL samples of intermediate-and high-grade histology derived from non-AIDS patients, no Ras mutations were detected using a combination of technical approaches42 (and our unpublished data, December 199 1). Several mutagenic carcinogens are capable of inducing Ras mutations5'; however, since the Ras-positive AIDS-NHL samples were derived from untreated patients, these mutations cannot be attributed to the well-established mutagenic effects of antiviral therapy,70 although this possibility must also be explored in future studies in treated patients.
Overall, this study documents that the repertoire of genetic lesions differs substantially in different histologic types of AIDS-NHL, and, therefore, AIDS-lymphomagenesis may be associated with distinct molecular pathways. Our analyses of c-myc, p53, RBI, Ras family genes, and EBV infection would suggest that at least two independent patterns of genetic lesions are observed in these tumors: on one side, NHL displaying SNCCL histology are strictly associated with c-myc deregulation and p53 inactivation, while EBV infection is present only in a subset of these tumors; on the other hand, a monoclonal EBV infection is consistently associated with systemic LC-IBPL AIDS-NHL, where additional unknown lesions may be necessary.
Finally, it is noteworthy that lymphomagenesis in the AIDS patient may be characterized by the accumulation of multiple (up to four) genetic lesions within a relatively short time (4  to 6 Other presently uncharacterized lesions may also be present based, for instance, on the finding that chromosome 6 deletions, involving the site of two putative tumor suppressor genes,71 are detectable in a sizable fraction of these tumors (G.G., D.M.K., R.D.-F., unpublished observation, March 1992). The rapid multilesional development of AIDS-NHL is in contrast with the general concept, mainly derived from solid tumors, that a long time period (30 to 40 years) is commonly associated with multistep tum~rigenesis.'~,'~ The high proliferative activity of AIDS-NHL may at least in part account for this di~crepancy'~: however, it remains to be explored whether AIDS-associated lymphomagenesis involves the rapid stochastic accumulation of genetic lesions caused by intrinsic genomic instability, or the mutually dependent selection of a number of synergizing lesions (eg, c-myc deregulation and p53 inactivation).
